SEER Inquiry System - Question 20180106 Details

System Guide

Back to Search Results

SEER Inquiry System - Report

Produced: 10/29/2025 9:33 AM

Question 20180106

Export CSV Export PDF Print

Add to Report

Inquiry Details

References:

NCI Drug Dictionary

Question:

First Course Treatment--Other Therapy: Please explain how to code this new therapy, peptide receptor radionuclide therapy (PRRT) for rare neuroendocrine tumors. See Discussion.

Discussion:

According to this article, PRRT treatment lutetium Lu 177 dotatate was approved earlier this year by the United States Food and Drug Administration for adult use. PRRT is a nuclear medicine therapy that travels throughout the body looking for a certain receptor within neuroendocrine tumors. These include pancreatic and small neuroendocrine tumors in the gastrointestinal tract. Once absorbed into the tumor, the radioactive material starts to break down tumor cells, killing them. It is the first radioactive drug approved for the targeted treatment of gastroenteropancreatic neuroendocrine tumors.

(http://cinj.org/rutgers-cancer-institute-new-jersey-and-robert-wood-johnson-university-hospital-are-first-state ).

Answer:

For cases diagnosed prior to 2023: Code Peptide Receptor Radionuclide Therapy (PRRT) in the data item Other Therapy, code 1, Other.

See SINQ 20220042 and 20230005 for information pertaining to cases diagnosed in 2023 or later.

Cancer Site Category:

N/A

Data Item Category:

First course treatment, Other therapy

Other Category:

N/A

Year:

2018